Evidence map›Paper›PMID 33419298›Full record

ArticleDiagnostics (Basel, Switzerland)2020

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers.

Francesca Giunchi, Francesco Massari, Annalisa Altimari, Elisa Gruppioni, Elisabetta Nobili, Michelangelo Fiorentino, Andrea Ardizzoni

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Exploring therapeutic applications ofFrontiers in oncology · 2025
    Review
  2. Review
  3. The Expression of Proto-OncogeneInternational journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Francesca GiunchiDepartment of Pathology, Azienda Ospedaliero-Universitaria di Bologna IRCCS Policlinico S.Orsola-Malpighi, Via Albertoni 15, 40138 Bologna, Italy.
Francesco MassariDepartment of Clinical Oncology, Azienda Ospedaliero-Universitaria di Bologna IRCCS Policlinico S.Orsola-Malpighi, Via Albertoni 15, 40138 Bologna, Italy.ORCID 0000-0001-6476-6871
Annalisa AltimariDepartment of Pathology, Azienda Ospedaliero-Universitaria di Bologna IRCCS Policlinico S.Orsola-Malpighi, Via Albertoni 15, 40138 Bologna, Italy.
Elisa GruppioniDepartment of Pathology, Azienda Ospedaliero-Universitaria di Bologna IRCCS Policlinico S.Orsola-Malpighi, Via Albertoni 15, 40138 Bologna, Italy.
Elisabetta NobiliDepartment of Clinical Oncology, Azienda Ospedaliero-Universitaria di Bologna IRCCS Policlinico S.Orsola-Malpighi, Via Albertoni 15, 40138 Bologna, Italy.
Michelangelo FiorentinoDepartment of Diagnostic Specialistic and Experimental Medicine, Alma Mater Studiorum University of Bologna School of Medicine, 40138 Bologna, Italy.ORCID 0000-0002-1749-150X
Andrea ArdizzoniDepartment of Clinical Oncology, Azienda Ospedaliero-Universitaria di Bologna IRCCS Policlinico S.Orsola-Malpighi, Via Albertoni 15, 40138 Bologna, Italy.
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TMPRSS2:ERG fusion is considered prostate specific and has been rarely described in other tumors. We describe the case of a patient who developed lung and prostate cancers, both harboring the TMPRSS2:ERG fusion. The patient developed a cancer of the prostate with lymph node metastases and after two years a nodule of the thoracic wall. The histology and immunohistochemical profile of the two tumors were typical of prostate and lung cancers. The presence of the TMPRSS2:ERG fusion was demonstrated by next-generation sequencing on both malignancies, leading to the assumption that the lung nodule was a metastasis from the prostate cancer. The patient failed to respond to antiandrogen therapy, while chemotherapy for lung cancer led to a significant objective response. To our knowledge, this is the first case of a lung cancer harboring the TMPRSS2:ERG fusion, widening the spectrum of lung cancer-associated molecular alterations.

Indexed as

lung cancernext-generation sequencingprostate cancerTMPRSS2:ERG fusion

Identifiers

PMID33419298
PMCPMC7765862
OpenAlexW3117653345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.